Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC96719 MAD and Food Effect in Healthy Subjects
NCT04546984Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hec96719 in Nonalcoholic steatohepatitis (NASH) (6 arms), sponsored by Sunshine Lake Pharma. Primary endpoint: Number of Adverse Events up to 17 days. Started Sep 2020; status: completed.
02
Drugs
hec96719
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04546984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04546984.